Envacgen (inactivated EV71 vaccine) / Medigen Biotech - LARVOL DELTA

A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years (clinicaltrials.gov) - P3 | N=378 | Recruiting | Sponsor: Medigen Vaccine Biologics Corp.

New P3 trial

Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study. (PubMed, Vaccines (Basel)) - "No long-term safety issues were reported. Our study provides novel insights into the long-term immunity conferred by EV71vac in children aged from two months to six years, particularly in those who received EV71vac between two and six months of age."

Journal • P2 data • CNS Disorders • Pediatrics